title: The use of octreotide to successfully treat protein-losing enteropathy following the Fontan operation.
abstract: Octreotide has had limited use for the treatment of protein-losing enteropathy following the Fontan operation. We describe three cases where subcutaneous octreotide was successfully used to treat refractory protein-losing enteropathy following the Fontan operation. Patients received octreotide therapy for a period of 14-28 months. Octreotide was discontinued in one patient due to symptomatic cholelithiasis; this patient died 7 months after treatment was discontinued. Octreotide may be a useful treatment in these patients, but further study on its efficacy and mechanism of action is needed.
authors.affiliation: Division of Cardiology, Children's National Medical Center, George Washington University, 111 Michigan Avenue NW,Washington, DC 20010, USA. anjohn@cnmc.org
authors.forename: Anitha S
authors.initials: AS
authors.lastname: John
authors.forename: Sabrina D
authors.initials: SD
authors.lastname: Phillips
authors.forename: David J
authors.initials: DJ
authors.lastname: Driscoll
authors.forename: Carole A
authors.initials: CA
authors.lastname: Warnes
authors.forename: Frank
authors.initials: F
authors.lastname: Cetta
mesh_terms: D000328:Adult; D002648:Child; D002769:Cholelithiasis / Q000139:chemically induced; D004334:Drug Administration Schedule; D005260:Female; D018729:Fontan Procedure / Q000009:adverse effects*; D006330:Heart Defects, Congenital / Q000601:surgery*; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011504:Protein-Losing Enteropathies / Q000188:drug therapy* / Q000209:etiology; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D015282:Octreotide